<p>Asahi Kasei is set to acquire Veloxis Pharmaceuticals Inc., a U.S.-based pharmaceutical company, through its Danish subsidiary. The transaction involves a voluntary tender offer for all ordinary shares and warrants of Veloxis Pharmaceuticals A/S, which owns 100% of Veloxis. The deal, valued at approximately USD 1.3 billion, is intended to accelerate Asahi Kasei’s transformation into a global health care company by strengthening its pharmaceutical presence in the U.S. market and creating synergies between its existing operations in Japan and Asia and Veloxis’ business platform in the United States. The acquisition aims to boost licensing activities, expand the pipeline of new pharmaceuticals, and enhance access to innovation and clinical practices in the U.S. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Asahi Kasei Corporation published the original content used to generate this news brief on January 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Reuters

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Asahi Kasei Corporation

SPDR S&P Biotech

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Vertex Pharma

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Asahi Kasei

Asahi Kasei to Acquire Veloxis Pharmaceuticals for $1.3 Billion